- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01725958
Effects of a Nutritional Supplement Combination on Body Weight Management
A Phase IV, Open-label, Parallel Group, Single-Center Study on the Effects of a Nutritional Supplement Combination on Body Weight Management Over a 90-day Period
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Safety assessment:
Safety will be assessed by changes in blood chemistries/hematology, and adverse events, of nutritional supplement emergent AEs (TEAEs), classified by severity grade, relatedness to the nutritional supplement.
Efficacy Assessment:
The objectives of this study are to evaluate the efficacy (changes in body composition and measurements as well as influence on appetite and quality of life changes) of the nutritional supplement administered repeatedly throughout the study.
Study Subject Population:
Healthy adult men and women are eligible for participation upon fulfillment of the inclusion/exclusion criteria.
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
Utah
-
Orem, Utah, United States, 84058
- Aspen Clinical Research
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Females and Males aged 25-65 years
- Signed informed consent
- BMI between 25 and 40 kg/m2
- A resting normotensive blood pressure is defined as a systolic blood pressure between 90-145 mmHg and a diastolic blood pressure of 50 90 mmHg
- Use of effective method of contraception by females of childbearing [potential and agreement to continue to practice an acceptable method of contraception for the duration of their participation in the study]. Acceptable methods of contraception include oral, injectable, or implantable contraceptives; intrauterine devices, diaphragm plus spermicide; abstinence (must agree to use double-barrier method if they become sexually active), transdermal patch, or any double barrier method including a vasectomized sexual partner. Women who have had a hysterectomy or tubal ligation at least 6 months prior to Visit 1 or who have been post-menopausal
- Ability to speak and understand English
- Willing to fast the morning of visit where blood samples are taken
Exclusion Criteria:
- Self-reported chronic condition that may affect subject safety (e.g., diabetes, cardiovascular disease) or significantly impact product effectiveness (e.g., chronic fatigue)
- Pregnancy/suspected pregnancy, breastfeeding or planning to become pregnant during the course of the study.
- Use of Antihypertensive medication for less than 4 months or unregulated clinically blood pressure.
- Having undergone gastroplasty or bariatric surgery in the past 10 years.
- Taking medication (e.g., thyroid medication), must be stable for at least four months.
- Allergies to any ingredients contained in the Nutritional Supplement.
- Medical treatment for insomnia or depression within 30-days prior to the screening visit.
- Tobacco (e.g. cigarettes, chewing tobacco, pipe, nicotine patches) use within 30-days prior to the screening visit.
- Planned surgical procedure during the course of the study.
- Currently participating in another study or have done so within 30 days prior to the screening visit or is likely to enroll in another clinical or nutritional study.
- Currently taking any medication or supplement for the use of weight loss must be discontinued prior to Visit 1 Baseline Day 0.
- Currently participating in a weight loss program or participated in a weight loss program in the past 6 months.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
EXPERIMENTAL: Dietary Supplement
Treatment Regimen -The Nutritional Supplement will be given for approximately 90 days in the form of 7 capsules and a powder to mix into liquids or foods for the first 15 days of program. Subjects will also drink a protein shake. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
-Evaluate the changes in body composition as determined by percent body fat using the Bod Pod
Time Frame: 90 Days
|
90 Days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Evaluate the changes in body weight
Time Frame: 90 days
|
|
90 days
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Study Director: Steve Poole, BS, Pharmanex
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- NSE 12-PHX-08-NU-02
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Safety/Effacy
-
Anne Estrup OlesenAalborg University; University College of Northern Denmark; Aalborg KommuneCompletedPatient Safety | Medication SafetyDenmark
-
Ondokuz Mayıs UniversityCompletedNursing Education | Patient Safety | Medication SafetyTurkey (Türkiye)
-
West China Second University HospitalCompletedDrug Safety | Drug Metabolism | Medication SafetyChina
-
Radboud University Medical CenterZonMw: The Netherlands Organisation for Health Research and DevelopmentTerminatedPatient Empowerment | Patient Safety | Medication SafetyNetherlands
-
The University of Texas Health Science Center,...CompletedMedical Education | Patient Safety | Educational Safety Curriculum | Surgical Resident
-
LadeRx LLCDuke Clinical Research InstituteNot yet recruiting
-
Korea Otsuka Pharmaceutical Co., Ltd.Completed
-
MicuRxWorldwide Clinical TrialsCompleted
-
Provention Bio, Inc.Completed
-
Chris Lascola, MDDuke UniversityWithdrawn
Clinical Trials on Nutritional supplement and protein shakes
-
Duke UniversityUnited States Department of Defense; Baxter Healthcare CorporationRecruiting
-
Duke UniversityCompletedCritical Illness | TraumaUnited States
-
University of CopenhagenRigshospitalet, DenmarkCompleted
-
Seoul National University Bundang HospitalMyongji HospitalTerminatedStroke | MalnutritionKorea, Republic of
-
Taipei Medical UniversityTaipei Medical University WanFang HospitalCompletedMalnutrition | Cancer of Liver | Nutrition Aspect of Cancer | Cancer of ColonTaiwan
-
Abbott NutritionCompletedGastro-Intestinal ToleranceUnited Kingdom
-
University Clinical Centre, GdanskNutricia FoundationUnknownQuality of Life | Metastatic Colorectal Cancer | Toxicity Due to Chemotherapy | Dietary Modification | Cancer CachexiaPoland
-
University Hospital, LimogesCompletedMalnutrition in the ElderlyFrance
-
Alexandria UniversityCompletedHemodialysis ComplicationEgypt
-
University College DublinFHI 360Active, not recruitingAging | Undernutrition | Appetite LossIreland